For family offices, institutions and qualifying private investors.
HMOCapital is raising equity in annual rounds to build a portfolio of 250 en-suite co-living homes, termed out on long-term debt at stabilisation and held until our target price is achieved. The information memorandum, financial model, structure and terms are held in a private data room, opened to investors we have approved.
250 houses, 1,825 en-suite rooms, £201m GDV.
Houses are bought and converted over four years, let room by room to working professionals, then termed out onto long-term mortgages once the portfolio is stabilised.
Equity is raised year by year, as the houses are bought.
Each annual round funds that year's acquisitions and conversions alongside development finance. Equity is called only as houses are bought, so capital is not left idle.
| Round | Houses acquired | Portfolio at year end | Acquisition and conversion spend | Equity raised |
|---|---|---|---|---|
| 2027 | 18 | 18 houses | £8.7m | £1.89m |
| 2028 | 50 | 68 houses | £26.7m | £2.38m |
| 2029 | 75 | 143 houses | £42.4m | £3.26m |
| 2030 | 107 | 250 houses | £63.7m | £5.89m |
| Total | 250 | 1,825 rooms | £147.6m | £13.42m |
HMOCapital financial model, October 2026, base case (first close 15 November 2026, 250 houses). GDV is the portfolio value on run-rate net operating income at a 7% yield. Spend includes purchase price, project management, stamp duty, legal and conversion costs; the final £6.0m of conversion work completes in 2031 and is funded by debt. These are model projections, not forecasts or promises. Capital is at risk.
- 01Request accessTell us who you are and confirm your investor category.
- 02We review your requestA member of the HMOCapital team approves each request personally, usually within one working day.
- 03Sign inOnce approved, we email you a secure sign-in link. There is no password to remember: each time you return, we email you a new link.
Already approved? Sign in to the data room.
Read the thesis behind the programme.
Our investment thesis sets out the market evidence, and our strategy explains how we create value. For anything else, get in touch.